COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

Search

Novo Nordisk A-S (Class B)

Slēgts

338.3 -2.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

334.8

Max

346.55

Galvenie mērījumi

By Trading Economics

Ienākumi

-2.5B

27B

Pārdošana

-1.2B

77B

P/E

Sektora vidējais

14.639

35.733

EPS

5.96

Dividenžu ienesīgums

3.25

Peļņas marža

34.484

Darbinieki

78,387

EBITDA

39B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+9.53% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.25%

3.13%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

238B

1.6T

Iepriekšējā atvēršanas cena

340.68

Iepriekšējā slēgšanas cena

338.3

Novo Nordisk A-S (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. aug. 13:52 UTC

Galvenie tirgus virzītāji

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

2025. g. 18. aug. 09:23 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025. g. 18. aug. 09:23 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025. g. 6. aug. 06:52 UTC

Peļņas

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

2025. g. 6. aug. 06:21 UTC

Peļņas

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2025. g. 2. sept. 09:14 UTC

Karstas akcijas

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

2025. g. 21. aug. 08:49 UTC

Peļņas
Karstas akcijas

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

2025. g. 18. aug. 09:23 UTC

Karstas akcijas

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

2025. g. 8. aug. 05:32 UTC

Tirgus saruna

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

2025. g. 7. aug. 11:32 UTC

Peļņas

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 11:03 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 10:41 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

2025. g. 6. aug. 20:34 UTC

Peļņas

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

2025. g. 6. aug. 08:45 UTC

Peļņas

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

2025. g. 6. aug. 07:19 UTC

Tirgus saruna
Peļņas

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

2025. g. 6. aug. 05:50 UTC

Peļņas

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

2025. g. 6. aug. 05:48 UTC

Peļņas

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

2025. g. 6. aug. 05:46 UTC

Peļņas

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

2025. g. 6. aug. 05:38 UTC

Peļņas

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

2025. g. 6. aug. 05:37 UTC

Peļņas

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

2025. g. 6. aug. 05:36 UTC

Peļņas

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

2025. g. 6. aug. 05:35 UTC

Peļņas

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

2025. g. 6. aug. 05:34 UTC

Peļņas

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

2025. g. 6. aug. 05:31 UTC

Peļņas

Novo Nordisk 2Q Net Pft DKK26.5B

2025. g. 6. aug. 05:31 UTC

Peļņas

Novo Nordisk 2Q Oper Pft DKK33.45B

2025. g. 6. aug. 05:31 UTC

Peļņas

Novo Nordisk 2Q Sales DKK76.86B

2025. g. 5. aug. 21:58 UTC

Peļņas

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025. g. 5. aug. 17:26 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

2025. g. 5. aug. 15:15 UTC

Peļņas

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

2025. g. 5. aug. 10:07 UTC

Tirgus saruna

Novo Nordisk's Facing Challenging Times -- Market Talk

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S (Class B) Prognoze

Cenas mērķis

By TipRanks

9.53% augšup

Prognoze 12 mēnešiem

Vidējais 1,162.73 DKK  9.53%

Augstākais 1,550 DKK

Zemākais 720 DKK

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S (Class B) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

2

Turēt

2

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat